By Scott Gottlieb (Original source Fierce Biotech)
“Scott Gottlieb’s relatively short two-year tenure as the FDA’s head has ended, and we have a new man at the helm: Ned Sharpless. However, he used his first official talk to ensure we all know he’s not looking to tear up Gottlieb’s legacy.
Gottlieb, in fact, denied to reporters at the start of the year that he was leaving, but a few short months later he announced he was doing exactly that (citing commuting times), and then preceded to have the world’s longest goodbye tour. Fitting, I suppose, for a rock’n’roll FDA commissioner.
Gottlieb was praised by many in the bio Twitter sphere, as well as by President Donald Trump, the man who appointed him as FDA commissioner. Some areas, though, namely the opioid crisis and the surge in an anti-vaxxer movement, which has also seen a related spike in measles cases in the U.S., are still areas the FDA must get a grip on.”
Click here to see more
Chris Miller: Trump admin believes tariff threats have led to more US chip investments
Chris Miller, Tufts Fletcher School associate professor and ‘Chip War’ author, joins ‘Squawk Box’ to discuss the U.S-China trade breakthrough, impact on the chips sector,…
Thought Leader: Chris Miller
Patrick McGee: How Apple invested big, profited greatly and sold itself to China
“Apple in China,” by Patrick McGee, tells the gripping tale of how the computer giant’s decades-long investment in China fueled its spectacular success and, in…
Thought Leader: Patrick McGee
Patrick McGee: How Apple helped China become America’s biggest tech rival
Apple in China: The Capture of the World’s Greatest Company by Patrick McGee (Simon & Schuster) is out on Tuesday. Apple relied on cheap Chinese labour…
Thought Leader: Patrick McGee
